RS65428B1 - Formulacije apiksabana - Google Patents
Formulacije apiksabanaInfo
- Publication number
- RS65428B1 RS65428B1 RS20240457A RSP20240457A RS65428B1 RS 65428 B1 RS65428 B1 RS 65428B1 RS 20240457 A RS20240457 A RS 20240457A RS P20240457 A RSP20240457 A RS P20240457A RS 65428 B1 RS65428 B1 RS 65428B1
- Authority
- RS
- Serbia
- Prior art keywords
- apixaban formulations
- apixaban
- formulations
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title 1
- 229960003886 apixaban Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658175P | 2018-04-16 | 2018-04-16 | |
| PCT/US2019/027456 WO2019204193A1 (en) | 2018-04-16 | 2019-04-15 | Apixaban formulations |
| EP19722333.2A EP3781132B1 (en) | 2018-04-16 | 2019-04-15 | Apixaban formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65428B1 true RS65428B1 (sr) | 2024-05-31 |
Family
ID=66429558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240457A RS65428B1 (sr) | 2018-04-16 | 2019-04-15 | Formulacije apiksabana |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11896586B2 (sr) |
| EP (2) | EP4353312A3 (sr) |
| JP (1) | JP7382957B2 (sr) |
| AU (1) | AU2019255599B2 (sr) |
| BR (1) | BR112020020941A2 (sr) |
| CA (1) | CA3097176A1 (sr) |
| DK (1) | DK3781132T3 (sr) |
| FI (1) | FI3781132T3 (sr) |
| HR (1) | HRP20240529T1 (sr) |
| LT (1) | LT3781132T (sr) |
| MX (1) | MX2020010673A (sr) |
| PL (1) | PL3781132T3 (sr) |
| PT (1) | PT3781132T (sr) |
| RS (1) | RS65428B1 (sr) |
| SG (1) | SG11202010097WA (sr) |
| SI (1) | SI3781132T1 (sr) |
| WO (1) | WO2019204193A1 (sr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140003A (zh) * | 2020-02-13 | 2021-11-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 阿哌沙班注射劑用於預防或者治療血栓栓塞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670567B2 (en) * | 1992-03-05 | 1996-07-25 | American Home Products Corporation | Pharmaceutical coated cores |
| ATE241969T1 (de) * | 1997-03-26 | 2003-06-15 | Janssen Pharmaceutica Nv | Tabletten mit einem kern, der mit einem pilzbekämpfungsmittel und einem polymeren beschichtet ist |
| TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
| PT2442791T (pt) | 2009-06-16 | 2020-02-06 | Pfizer | Formas farmacêuticas de apixaban |
| JP5846647B2 (ja) | 2010-02-25 | 2016-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アピキサバン製剤 |
| EP2554159A1 (en) * | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| MX351059B (es) * | 2012-08-17 | 2017-09-29 | Laboratorios Senosiain S A De C V Star | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. |
| US9452134B2 (en) * | 2012-09-26 | 2016-09-27 | Bristol-Myers Squibb Company | Apixaban solution formulations |
| CN105663049A (zh) * | 2014-11-22 | 2016-06-15 | 哈尔滨圣吉药业股份有限公司 | 一种阿哌沙班缓释微丸及其制备方法 |
| US10413543B2 (en) * | 2015-09-01 | 2019-09-17 | Sun Pharma Advanced Research Company Ltd. | Stable multiparticulate pharmaceutical composition of rosuvastatin |
| CN106913528A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技（武汉）有限公司 | 阿哌沙班微丸及其制备方法 |
-
2019
- 2019-04-15 BR BR112020020941-4A patent/BR112020020941A2/pt unknown
- 2019-04-15 DK DK19722333.2T patent/DK3781132T3/da active
- 2019-04-15 MX MX2020010673A patent/MX2020010673A/es unknown
- 2019-04-15 PT PT197223332T patent/PT3781132T/pt unknown
- 2019-04-15 JP JP2020556976A patent/JP7382957B2/ja active Active
- 2019-04-15 SI SI201930748T patent/SI3781132T1/sl unknown
- 2019-04-15 WO PCT/US2019/027456 patent/WO2019204193A1/en active Application Filing
- 2019-04-15 HR HRP20240529TT patent/HRP20240529T1/hr unknown
- 2019-04-15 EP EP24159997.6A patent/EP4353312A3/en active Pending
- 2019-04-15 SG SG11202010097WA patent/SG11202010097WA/en unknown
- 2019-04-15 AU AU2019255599A patent/AU2019255599B2/en active Active
- 2019-04-15 LT LTEPPCT/US2019/027456T patent/LT3781132T/lt unknown
- 2019-04-15 CA CA3097176A patent/CA3097176A1/en active Pending
- 2019-04-15 EP EP19722333.2A patent/EP3781132B1/en active Active
- 2019-04-15 US US17/047,428 patent/US11896586B2/en active Active
- 2019-04-15 RS RS20240457A patent/RS65428B1/sr unknown
- 2019-04-15 PL PL19722333.2T patent/PL3781132T3/pl unknown
- 2019-04-15 FI FIEP19722333.2T patent/FI3781132T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7382957B2 (ja) | 2023-11-17 |
| JP2021521242A (ja) | 2021-08-26 |
| LT3781132T (lt) | 2024-04-25 |
| PL3781132T3 (pl) | 2024-05-20 |
| AU2019255599A1 (en) | 2020-11-12 |
| EP4353312A2 (en) | 2024-04-17 |
| CA3097176A1 (en) | 2019-10-24 |
| MX2020010673A (es) | 2020-10-28 |
| FI3781132T3 (fi) | 2024-05-31 |
| AU2019255599B2 (en) | 2024-02-29 |
| EP3781132B1 (en) | 2024-03-20 |
| EP4353312A3 (en) | 2024-07-17 |
| US20210145817A1 (en) | 2021-05-20 |
| DK3781132T3 (da) | 2024-04-22 |
| BR112020020941A2 (pt) | 2021-03-02 |
| WO2019204193A1 (en) | 2019-10-24 |
| EP3781132A1 (en) | 2021-02-24 |
| SI3781132T1 (sl) | 2024-07-31 |
| SG11202010097WA (en) | 2020-11-27 |
| US11896586B2 (en) | 2024-02-13 |
| PT3781132T (pt) | 2024-05-16 |
| HRP20240529T1 (hr) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL268697A (en) | Formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL273282A (en) | Niraprib formulations | |
| GB201809976D0 (en) | Novel formulations | |
| IL287224A (en) | New formulations containing melphalan | |
| GB201707189D0 (en) | Novel formulations | |
| GB201707188D0 (en) | Novel formulations | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| PT4045038T (pt) | Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida | |
| IL290356A (en) | Formulations for Resotide | |
| GB201707187D0 (en) | Novel formulations | |
| IL284691A (en) | formulations | |
| SG11202010097WA (en) | Apixaban formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201911063D0 (en) | Formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB201905105D0 (en) | Formulations | |
| GB201808386D0 (en) | Formulations | |
| GB201804545D0 (en) | Formulations | |
| GB201803201D0 (en) | Formulations | |
| GB201910092D0 (en) | New formulations | |
| GB201910093D0 (en) | New formulations | |
| GB201806498D0 (en) | Novel formulation |